<DOC>
	<DOC>NCT00313170</DOC>
	<brief_summary>This study will assess the relationship between fulvestrant dose and efficacy in postmenopausal women with oestrogen receptor positive advanced breast cancer.</brief_summary>
	<brief_title>A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Breast Cancer has continued to grow after having received treatment with an antiestrogen hormonal treatment such as tamoxifen or an aromatase inhibitor. Requiring hormonal treatment. Postmenopausal women (woman who has stopped having menstrual periods) Treatment with more than one previous regimen of systemic anticancer therapy other than endocrine therapy for advanced BC. Treatment with more than one previous regimen of endocrine therapy for advanced BC. An existing condition that prevents compliance.</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>oncology</keyword>
	<keyword>cancer</keyword>
	<keyword>breast cancer</keyword>
</DOC>